Tech Company Financing Transactions
Therini Bio Funding Round
Angelini Ventures, Apollo Health Ventures and Dolby Family Ventures participated in a $39 million Series A funding round for Therini Bio. The round was announced on 5/14/2025.
Transaction Overview
Company Name
Announced On
5/14/2025
Transaction Type
Venture Equity
Amount
$39,000,000
Round
Series A
Investors
Proceeds Purpose
Proceeds are being used to fund Phase 1b Alzheimer's and DME studies, and bispecific development
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
681 Gateway Blvd. 411
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Therini Bio, Inc. is a biotechnology company dedicated to the research and development of novel therapeutics for the treatment of neuroinflammatory diseases due to vascular dysfunction. Our approach will be generally applicable across a range of inflammatory diseases including peripheral indications.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Daniel Burgess
Founder
Katerina Akass
Browse more venture capital transactions:
Prev: 5/14/2025: VFlowTech venture capital transaction
Next: 5/14/2025: Gnosis venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to document every notable VC transaction. VC transactions on this site are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs